Current and Future Therapeutic Approaches in Colorectal and Gastric Cancer: Immunotherapy - Ep 2

Episode 2 • October 21, 2021 • 00:18:13
Current and Future Therapeutic Approaches in Colorectal and Gastric Cancer: Immunotherapy - Ep 2
COR2ED Medical Education
Current and Future Therapeutic Approaches in Colorectal and Gastric Cancer: Immunotherapy - Ep 2

Oct 21 2021 | 00:18:13

/

Show Notes

In this podcast series, Dr. Jenny Seligmann (University of Leeds, UK), Dr. Autumn McRee (University of North Carolina, USA) and Dr. Dominik Modest (Charité University of Medicine, Germany) discuss the different therapeutic options available in colorectal and gastric cancer.

This second episode focuses on recent developments in immunotherapy approaches in metastatic colorectal and gastric cancer – specifically whether immunotherapy should be used alone, in combination with other treatments or with chemotherapy. Data from several clinical trials are discussed such as KEYNOTE-177, CheckMate 142, CheckMate 649, KEYNOTE 062, and NICHE. The experts also consider the appropriate treatment regimens for MSI-high and MSS colorectal and gastric cancer patients and whether CPS is an appropriate biomarker for gastric cancer.

Other Episodes

Episode 19

August 23, 2023 • 00:20:58
Episode Cover

Monitoring anticoagulation: yes or no?

COR2ED Medical Education: In this podcast episode, Prof Dimitrios Tsakiris (Haematologist, Basel University, Switzerland) and Assoc. Prof. Michael Nagler (Haematologist, Inselspital University Hospital, Bern,...

Listen

Episode

October 25, 2023 • 00:25:38
Episode Cover

VTE: how long should anti-thrombotic treatment be?

COR2ED Medical Education: Extended anticoagulation beyond the initial 3 months is indicated for all types of VTE, except in surgery-or trauma-VTE or in patients...

Listen

Episode 2

October 03, 2021 • 00:16:30
Episode Cover

ASBMR 2021 Rare Bone Disease Highlights from Day Two

We have partnered with international experts to provide rare bone diseases highlights from ASBMR 2021. This is the second in a series of four...

Listen